Stockscreener 앱 받기
8.78
2.01%
-0.18
시간 외 거래:
8.75
-0.03
-0.34%
Replimune Group Inc 주식(REPL)의 최신 뉴스
REPL Stock On Track To Hit All-Time Lows – Here’s Why This Analyst Slashed Price Target By 85% - Stocktwits
REPL nosedives as FDA chief stands firm against melanoma treatment: ‘I don’t work for Replimune’ - MSN
REPL Stock On Track For Worst Drop In Nearly 7 Months Ahead Of FDA Decision On Skin Cancer Drug - Stocktwits
Replimune Group Stock Short Interest Rises to 56.4% - Quiver Quantitative
REPL stock soars on plans of BLA resubmission for melanoma combo drug - MSN
REPL Vs IOVA: FDA Decision Day Could Test Biotech Bulls’ Conviction On These Melanoma Plays - Stocktwits
Replimune: Modeling The Coin Flip Of FDA Approval - Seeking Alpha
Replimune CCO Sarchi sells $110,880 in stock By Investing.com - Investing.com South Africa
Insider Sell: Christopher Sarchi Sells 12,000 Shares of Replimune Group Inc (REPL) - GuruFocus
Replimune CCO Sarchi sells $110,880 in stock - Investing.com
Replimune (REPL) CCO sells 12,000 shares under 10b5-1 plan - Stock Titan
Replimune surges on plans to resubmit lead drug for FDA review - MSN
REPL Stock Shot Up 80% Today – What’s The Deal With FDA? - Stocktwits
REPL Maintains Rating by Wedbush -- Price Target Raised to $6.00 - GuruFocus
REPL Stock Soars on Plans of BLA Resubmission for Melanoma Combo Drug - Yahoo Finance
Replimune Group Price Target Raised to $6.00/Share From $2.00 by Wedbush - Moomoo
Replimune Group Is Maintained at Neutral by Wedbush - Moomoo
Why Is Replimune Stock Gaining Monday? - Benzinga
Replimune Group (REPL) Is Up 77.0% After FDA Prioritizes RP1 Melanoma BLA Resubmission PathHas The Bull Case Changed? - simplywall.st
Why is REPL stock gaining in pre-market today? - MSN
Why Is REPL Stock Gaining In Pre-Market Today? - Yahoo Finance
Replimune plans RP1 BLA resubmission - The Pharma Letter
Palomar Holdings, Replimune Group, Snowflake - TradingView
US FDA Consistency Questions Remain As Replimune Eyes Third Shot At RP1 Approval - Citeline News & Insights
JPMorgan upgrades Replimune stock rating on FDA resubmission path - Investing.com
JPMorgan upgrades Replimune stock rating on FDA resubmission path By Investing.com - Investing.com Australia
REPL Stock Quote Price and Forecast - CNN
Top Biotech Gainers: REPL On Track, SNSE Awaits Phase 2 Data, Keep An Eye On CCCC, IMRX Soars - RTTNews
REPL stock shot up 80% today – what’s the deal with FDA? - MSN
$Replimune (REPL.US)$ - Moomoo
Replimune (REPL) Reports Promising Survival Data from IGNYTE Tri - GuruFocus
Replimune (REPL) Reports Positive Data from RP2 Trials for Advan - GuruFocus
Replimune (REPL) Reports Positive Data from RP2 Trials for Advanced Tumors - GuruFocus
Replimune (REPL) Reports Promising Survival Data from IGNYTE Trial - GuruFocus
REPL Technical Analysis & Stock Price Forecast - Intellectia AI
Replimune Group Presents Final First-in-Human Data for RP2 Oncolytic Immunotherapy at ASCO 2026 - Quiver Quantitative
Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting - The Manila Times
Replimune (REPL) Gains FDA Support for RP1 Resubmission - GuruFocus
Replimune Group Inc. has released the latest data on its candidate therapy Rp1 in combination with nivolumab, showing remarkable long-term survival benefits in patients with advanced melanoma who have developed resistance to PD-1 therapies, with a me - Bitget
Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting - The Daily Tribune News
Replimune Group Says Rp1 Plus Nivolumab Achieves Median Overall Survival Of 32.9 Months In Anti-Pd-1-Failed Melanoma - TradingView
Nearly half of anti-PD-1-failed melanoma alive 3 years with Replimune combo - Stock Titan
Replimune gets third chance at US approval for skin cancer drug | Business Information & News | FE - Westlaw Today
How Replimune's Drug Got Third Chance After White House Intervention -- WSJ - Moomoo
Exclusive | How Replimune’s Drug Got Third Chance After White House Intervention - WSJ
Replimune takes third swing at cancer drug approval following ‘productive’ FDA talks - BioPharma Dive
1.27%
1.43%
자본화:
|
볼륨(24시간):